quercetin-3-o-glucopyranoside has been researched along with hyperforin* in 2 studies
1 review(s) available for quercetin-3-o-glucopyranoside and hyperforin
| Article | Year |
|---|---|
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
The example of St. John's wort offers convincing evidence for the concept that modern methods of pharmacological and phytochemical research are effective in advancing the development of traditional herbal remedies. As a consequence of these efforts, it is known today that several compounds from different structural groups and with different mechanisms of action seem to be responsible for the observed antidepressant efficacy of St. John's Wort. Co-effectors in the extract improve the bioavailability of active constituents such as hypericin (1) (pharmacokinetic synergy). Unwanted side effects are preventable without remarkable loss of activity when the responsible constituent(s) are carefully removed during the extraction process, as demonstrated for hyperforin (3), which is responsible for the induction of cytochrome P450 (CYP)-metabolizing enzymes (CYP3A4, in particular). On the basis of our findings, it is likely that positive interactions between single compounds occur more frequently in traditionally used herbal preparations than is known presently. Topics: Anthracenes; Antidepressive Agents; Bridged Bicyclo Compounds; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Hypericum; Molecular Structure; Perylene; Phloroglucinol; Plant Preparations; Plants, Medicinal; Terpenes | 2010 |
1 other study(ies) available for quercetin-3-o-glucopyranoside and hyperforin
| Article | Year |
|---|---|
Hyperforin and Miquelianin from St. John's Wort Attenuate Gene Expression in Neuronal Cells After Dexamethasone-Induced Stress.
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis plays an important part in the development of depressive symptoms. In this study, the effects of a commercial St. John's wort extract (STW3-VI), hyperforin, miquelianin, and the selective serotonin reuptake inhibitor citalopram on the expression of genes relevant to HPA axis function were investigated in human neuronal cells. SH-SY5Y cells were treated with STW3-VI (20 µg/mL), hyperforin (1 µM), miquelianin (10 µM), or citalopram (10 µM) in the presence of the glucocorticoid receptor agonist dexamethasone (DEX,10 µM) for 6 h and 48 h, respectively. Quantitative real-time polymerase chain reaction was used to determine the expression of FKBP5 (FK506 binding protein 51), CREB (cAMP responsive element binding protein), GRIK4 (glutamate ionotropic receptor kainate type subunit 4), VEGF (vascular endothelial growth factor), NET (norepinephrine transporter), and ARRB ( Topics: Biomarkers; Cell Line; Dexamethasone; Gene Expression Regulation; Glucosides; Humans; Hypericum; Neurons; Phloroglucinol; Quercetin; Stress, Physiological; Terpenes | 2018 |